Want to join the conversation?
Steve Scala with Cowen asks about the upcoming KEYTRUDA PDUFA in head and neck cancer, should it be assumed approval will be only for third line PD-L1 positive patients. $MRK said in terms of approval, it cannot be commented what exactly the label will look like.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.